Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 2,671 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control II Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B); Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more

Conditions: Posterior Blepharitis, Meibomian Gland Dysfunction
Interventions: AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle; Drug
Lead sponsor: AxeroVision, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Neoplasms, Pain
Interventions: Lidocaine; Drug
Lead sponsor: San Diego Hospice & Palliative Care; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: LCZ696, Valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 4,822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 110
States / cities: Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more

Conditions: Depression, Post-traumatic Stress Disorder, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: support group therapy, educational intervention; Procedure · Other
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Nevada City, California • Stanford, California

Conditions: Postoperative Pain, Hip Arthroscopy
Interventions: Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline; Procedure · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Autism
Interventions: Playground Intervention, STAT Intervention; Behavioral
Lead sponsor: Health Resources and Services Administration (HRSA); Federal
Eligibility: 4 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, New York • Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more

Conditions: Autism Spectrum Disorder
Interventions: Floreo VR Building Social Connections, Sham; Device
Lead sponsor: Floreo, Inc.; Industry
Eligibility: 4 Years to 10 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Thousand Oaks, California

Conditions: Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Behavioral, Psychological or Informational Intervention, Educational Intervention, Medical Examination Assessment, Quality-of-Life Assessment, Survey Administration, Telephone-Based Intervention; Other · Procedure · Behavioral
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 113
States / cities: Fort Smith, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 66 more

Conditions: Covid19
Interventions: Alvelestat, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Autism Spectrum Disorder
Interventions: Placebo, RG7314; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 56
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 26 more

Conditions: Diabetes, Hypertension, Depression, Osteoarthritis, Asthma, Pain, Heart Failure
Interventions: Continuing Medical Education, Quality IQ Patient Simulations; Other
Lead sponsor: Qure Healthcare, LLC; Industry
Eligibility: Not listed
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer Disease
Interventions: DBS-f On, DBS Off; Device
Lead sponsor: Functional Neuromodulation Ltd; Industry
Eligibility: 65 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more

Conditions: Reversible Pulpitis, Dental Pulp Diseases
Interventions: NeoMTA, ProRoot MTA; Biological · Other
Lead sponsor: Texas A & M University Baylor College Of Dentistry; Other
Eligibility: 2 Years to 8 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis
Interventions: Atacicept, Placebo matched to atacicept; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions: MLN0128, MLN0128 (RP2D), Sorafenib; Drug
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Chapel Hill, North Carolina + 2 more

Conditions: Vulvodynia
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Miami, Florida • Kansas City, Missouri + 4 more

Conditions: Sclerosis, Systemic
Interventions: Placebo, tocilizumab [RoActemra/Actemra]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 18 more

Conditions: Brain Tumor
Interventions: C-SMART, BE Well; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Carcinoma, Non- Small Cell Lung
Interventions: Durvalumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Long Beach, California • Los Angeles, California • Daytona Beach, Florida + 7 more

Conditions: Covid-19, Sars-CoV2, Pneumonia
Interventions: Low dose radiation 35 cGy, High dose radiation 100 cGy; Radiation
Lead sponsor: Ohio State University; Other
Eligibility: 50 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 6
States / cities: Boca Raton, Florida • Miami, Florida • Maywood, Illinois + 3 more

Conditions: Prostate Cancer
Interventions: temsirolimus; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

Intravenous (IV) Lidocaine for Opioid-refractory Pain

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Phase I: At-Home Support for Rural Women Using Group Video Calling

PENG Block for Arthroscopic Hip Surgery

Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD)

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers

COVID-19 Study of Safety and Tolerability of Alvelestat

A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)

Quality IQ Patient Simulation Physician Practice Measurement and Engagement

ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Dysport in Vulvodynia Phase II Study

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

C-SMART vs BE Well for Patients With Brain Tumors

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

CCI-779 in Treating Patients With Prostate Cancer